[go: up one dir, main page]

YU401A - Agents with an antidepressive effect - Google Patents

Agents with an antidepressive effect

Info

Publication number
YU401A
YU401A YU401A YU401A YU401A YU 401 A YU401 A YU 401A YU 401 A YU401 A YU 401A YU 401 A YU401 A YU 401A YU 401 A YU401 A YU 401A
Authority
YU
Yugoslavia
Prior art keywords
agents
antidepressive effect
antidepressive
effect
benzothizole
Prior art date
Application number
YU401A
Other languages
Serbo-Croatian (sh)
Inventor
Jerzy Maj
Original Assignee
Boehringer Ingelheim Pharma Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Kg. filed Critical Boehringer Ingelheim Pharma Kg.
Publication of YU401A publication Critical patent/YU401A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the use of 2-amino-4,5,6,7-tetrahydro-6-propylamino-benzothizole (pramipexol), its (+) or (-) enantiomers or one of its pharmacologically compatible salts, combined with sertralin, for treating depression and depressive conditions more effectively.
YU401A 1998-07-07 1999-07-02 Agents with an antidepressive effect YU401A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19830201A DE19830201A1 (en) 1998-07-07 1998-07-07 Antidepressant

Publications (1)

Publication Number Publication Date
YU401A true YU401A (en) 2003-10-31

Family

ID=7873155

Family Applications (1)

Application Number Title Priority Date Filing Date
YU401A YU401A (en) 1998-07-07 1999-07-02 Agents with an antidepressive effect

Country Status (32)

Country Link
US (1) US6255329B1 (en)
EP (1) EP1093369B1 (en)
JP (1) JP2002520273A (en)
KR (1) KR100557692B1 (en)
CN (1) CN1230168C (en)
AR (1) AR019896A1 (en)
AT (1) ATE228365T1 (en)
AU (1) AU762128B2 (en)
BG (1) BG64972B1 (en)
BR (1) BR9911768A (en)
CA (1) CA2336833C (en)
CZ (1) CZ294087B6 (en)
DE (2) DE19830201A1 (en)
DK (1) DK1093369T3 (en)
EA (1) EA003142B1 (en)
EE (1) EE04296B1 (en)
ES (1) ES2183583T3 (en)
HU (1) HUP0103922A3 (en)
ID (1) ID27776A (en)
IL (1) IL140603A0 (en)
MY (1) MY117969A (en)
NO (1) NO20010064L (en)
NZ (1) NZ509729A (en)
PL (1) PL195043B1 (en)
PT (1) PT1093369E (en)
RS (1) RS49795B (en)
SK (1) SK284923B6 (en)
TR (1) TR200100146T2 (en)
TW (1) TW592698B (en)
WO (1) WO2000002542A2 (en)
YU (1) YU401A (en)
ZA (1) ZA200100090B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301899C (en) * 1998-07-27 2008-11-18 Boehringer Ingelheim Pharma Kg Agent with an antidepressant activity
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
DE10138275A1 (en) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Connections to eliminate anhedonia
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
EP2305252A1 (en) * 2001-12-11 2011-04-06 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
DE10334187A1 (en) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituted 2-aminotetralins for the treatment of depression
DE10334188B4 (en) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Use of rotigotine to treat depression
CA2554616A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
JP2009504748A (en) * 2005-08-15 2009-02-05 ユニバーシティ オブ バージニア パテント ファウンデーション Nerve recovery with R (+) pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
KR20090021169A (en) 2006-05-16 2009-02-27 크놉 뉴로사이언시스 인코포레이티드 Compositions comprising R (+) and S (-) pramipexole and methods of use thereof
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP2010521496A (en) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． Synthesis of chiral purified substituted benzothiazolediamine
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
ES2459322T3 (en) 2008-09-05 2014-05-09 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit hyperactivity disorder (ADHD)
CA2760527A1 (en) * 2009-04-30 2010-11-04 Supernus Pharmaceuticals, Inc. Method of treatment of depression
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
MX356727B (en) 2012-02-08 2018-06-12 Supernus Pharmaceuticals Inc Modified release formulations of viloxazine.
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES3043076T3 (en) 2013-07-12 2025-11-24 Areteia Therapeutics Inc Treating elevated levels of eosinophils and/or basophils
EP3038467B1 (en) 2013-08-13 2020-07-29 Knopp Biosciences LLC Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
IL312486B2 (en) * 2017-04-10 2025-05-01 Chase Therapeutics Corp Nk1-antagonist combination and method for treating synucleinopathies
KR20200026920A (en) 2017-06-30 2020-03-11 체이스 테라퓨틱스 코포레이션 NK-1 antagonist compositions for treating depression and methods for use in treating depression
CN110028464B (en) * 2019-04-26 2022-11-18 浙江海洋大学 Antarctic fungus secondary metabolism derivative BTZ-one and preparation method and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
EP0186087B1 (en) * 1984-12-22 1989-08-23 Dr. Karl Thomae GmbH Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
DE3843227A1 (en) * 1988-12-22 1990-07-05 Boehringer Ingelheim Kg NEW USE OF 2-AMINO-6-N-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZTHIAZOLE
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
DE3937271A1 (en) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg TRANSDERMAL APPLICATION OF 2-AMINO-6-N-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
DE4241013A1 (en) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Use of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole as antidepressant drug
JP3947582B2 (en) * 1995-08-15 2007-07-25 中外製薬株式会社 Anxiety treatment
ES2246058T3 (en) * 1996-03-29 2006-02-01 Pfizer Inc. BENCIL DERIVATIVES (IDEN) -LACTAMA, ITS PREPARATION AND ITS USE AS (ANT) 5-HT1A AND / OR 5-HT1D SELECTIVE AGONISTS.
CA2273809A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating movement disorders
CN1293573A (en) * 1998-01-13 2001-05-02 同步神经元有限责任公司 Methods of treating tardive dyskinesia and other movement disorders

Also Published As

Publication number Publication date
AR019896A1 (en) 2002-03-20
CA2336833C (en) 2008-09-23
ATE228365T1 (en) 2002-12-15
KR100557692B1 (en) 2006-03-07
EE200100014A (en) 2002-06-17
BG105112A (en) 2001-10-31
CN1308533A (en) 2001-08-15
EA200100084A1 (en) 2001-08-27
ZA200100090B (en) 2002-04-04
WO2000002542A2 (en) 2000-01-20
EA003142B1 (en) 2003-02-27
CA2336833A1 (en) 2000-01-20
CZ200177A3 (en) 2001-06-13
DK1093369T3 (en) 2002-12-16
US6255329B1 (en) 2001-07-03
DE59903556D1 (en) 2003-01-09
AU5030399A (en) 2000-02-01
KR20010079491A (en) 2001-08-22
EP1093369A2 (en) 2001-04-25
BR9911768A (en) 2001-04-03
SK112001A3 (en) 2001-10-08
TR200100146T2 (en) 2001-07-23
JP2002520273A (en) 2002-07-09
WO2000002542A3 (en) 2000-06-22
NZ509729A (en) 2003-06-30
NO20010064L (en) 2001-03-02
HK1037976A1 (en) 2002-03-01
TW592698B (en) 2004-06-21
CN1230168C (en) 2005-12-07
ES2183583T3 (en) 2003-03-16
SK284923B6 (en) 2006-02-02
DE19830201A1 (en) 2000-01-13
HUP0103922A3 (en) 2002-08-28
RS49795B (en) 2008-06-05
NO20010064D0 (en) 2001-01-05
IL140603A0 (en) 2002-02-10
AU762128B2 (en) 2003-06-19
MY117969A (en) 2004-08-30
EP1093369B1 (en) 2002-11-27
PL345842A1 (en) 2002-01-14
PT1093369E (en) 2003-03-31
CZ294087B6 (en) 2004-10-13
PL195043B1 (en) 2007-08-31
HUP0103922A2 (en) 2002-03-28
BG64972B1 (en) 2006-11-30
ID27776A (en) 2001-04-26
EE04296B1 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
YU401A (en) Agents with an antidepressive effect
CA2301899A1 (en) Agent with an antidepressant activity
MXPA02000973A (en) Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists.
BR0007527A (en) Phenylphenanthridines with IV-dependent inhibitory activity
BG106586A (en) Pyrazolopyramidines as therapeutic agents
BG104247A (en) Resorcinol derivatives
DE60112974D1 (en) Carbolinderivate
NO20013444D0 (en) Triazole compounds with the dopamine D3 receptor affinity
BG104780A (en) Inhibitors of phospholipase enzymes
TR200003004T2 (en) Heterocyclic substituted amides as calpain inhibitors
YU19499A (en) Benzonaphthyridines as bronchial therapeutics
ATE402149T1 (en) HETEROCYCLIC SUBSTITUTED AMIDES, THEIR PREPARATION AND USE
MXPA02010088A (en) Antitumoral ecteinascidin derivatives.
DE60216233D1 (en) Carbolinderivate
TR200003071T2 (en) New heterocyclic substituted amides with cysteine-protease effect
NO20005290D0 (en) Riluzole and levodopa combinations for the treatment of Parkinson's disease
SI1086096T1 (en) Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors
DK1463735T3 (en) Imidazo-2,1-B -1,3,4-thiadiazole sulfonamides
BR9914848A (en) Composition and process for the treatment of disorders of the external retina
BG105710A (en) 5ht1 antagonists for antidepressant therapy
MY124078A (en) Eletriptan hydrobromide monohydrate
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
IL142803A0 (en) Pharmaceutical compositions containing r-tofisopam
DK1204659T3 (en) Serotonergic benzofurans
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent